Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter
Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on year growth
Strong pipeline progress in 2023: Approval and launch of first pathogen targeted antibacterial XACDURO® for treatment of HABP/VABP caused by Acinetobacter infections; positive topline Phase 3 data for oral drug zoliflodacin for treatment of uncomplicated gonorrhea
Repurchased 1.1 million our common stock for $15.4 million in the fourth quarter of 2023
BURLINGAME, Calif., February 29, 2024--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.
Pavel Raifeld, Chief Executive Officer of Innoviva, said: "2023 was a successful and transformational year for Innoviva. We have seen continued strong cash flow from our core royalty portfolio, which we have been investing prudently with a laser focus on driving long-term shareholder value. Last year showcased the success of our approach with the formation and significant pipeline and commercial progress of our therapeutics platform, which is focused on becoming the industry leader in critical care and infectious disease."
Matthew Ronsheim, Ph.D., President of IST, noted, "Our therapeutics platform achieved tremendous success in its first year: we saw the approval and launch of XACDURO®, the first pathogen targeted antibacterial approved by the FDA for life threatening Acinetobacter infections caused by susceptible isolates; we reported positive Phase III data for zoliflodacin, the potential first novel oral treatment for gonorrhea; and our targeted and lean commercial platform delivered meaningful growth in our core marketed products GIAPREZA® and XERAVA®. With our best-in-class capabilities and leverageable commercial infrastructure, we are excited about our ability to deliver life-saving drugs to patients in areas of high unmet medical need and about our significant growth prospects in the coming years."
Mr. Raifeld concluded, "Innoviva’s strong financials reflect a new royalty base (following value-accretive 2022 TRELEGY® ELLIPTA® royalties monetization), a full year of integrated operations for our therapeutics platform, and significant value creation in our strategic healthcare assets. Innoviva continued to exercise financial discipline and ended the year with over $275 million in cash and account receivables, while returning capital with share repurchases of over $75 million and paying down outstanding debt of nearly $100 million. We believe our diversified growth strategy, a strong leadership team, and our focus on cost discipline position us well to deliver shareholder value."
Financial Highlights
Royalty revenue: Fourth quarter 2023 gross royalty revenue from Glaxo Group Limited ("GSK") was $69.6 million and full year was $252.7 million, compared to $54.7 million for the fourth quarter of 2022 and $253.4 million for the full year 2022.
Net Product Sales: Fourth quarter 2023 net product sales and license revenue were $19.7 million, which included $13.1 million from GIAPREZA®, $5.2 million from XERAVA®, and $1.4 million from XACDURO®, compared to $14.6 million for the fourth quarter of 2022. Full year 2023 net product sales and license revenue was $71.6 million, which included $41.3 million from GIAPREZA®, $17.3 million from XERAVA®, $2.0 million from XACDURO®, and $11.0 million in milestone payments from our partners.
Equity and long-term investments: Fourth quarter and full year 2023 change in fair values of equity and long-term investments of $25.5 million and $88.5 million, respectively, was primarily attributable to Armata Pharmaceuticals ("Armata") share price appreciation.
Net income: Fourth quarter 2023 net income was $61.5 million, or $0.97 basic per share, compared to a net loss of $68.3 million, or $(0.98) basic per share, for the fourth quarter 2022, driven primarily by higher revenue and positive impact of change in fair values of equity. Full year 2023 net income was $179.7 million, or $2.75 basic per share, compared to net income of $213.9 million, or $3.07 basic per share, for the full year 2022.
Share repurchase: During the fourth quarter 2023, Innoviva repurchased 1,121,835 shares of its outstanding common stock for $15.4 million. During the year 2023, Innoviva repurchased 6,173,565 shares of its outstanding common stock for $76.5 million. Approximately $15 million of the authorized program remains outstanding as of year-end.
Cash and cash equivalents: Totaled $193.5 million. Royalty and net product sales receivables totaled $84.1 million as of December 31, 2023.
Key 2023 R&D Highlights
Zoliflodacin: potential first-in-class oral antibiotic to treat uncomplicated gonorrhea
In November 2023, in collaboration with The Global Antibiotic Research & Development Partnership (GARDP), Innoviva announced that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in a global pivotal phase 3 clinical trial for the treatment of uncomplicated gonorrhea. The Company expects a New Drug Application to be submitted to the U.S. FDA in the next twelve months.
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use: targeted antibacterial for HABP/VABP caused by Acinetobacter
In May 2023, the U.S. Food and Drug Administration (FDA) approved XACDURO® for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Earlier in May, The Lancet Infectious Diseases published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam.
Update on Strategic Healthcare Assets
Our portfolio of strategic assets under the Company’s various subsidiaries was valued at $561.0 million as of December 31, 2023. In fourth quarter 2023, Innoviva invested an additional $5.0 million in one of our assets, Gate Neurosciences, to support its strategy of developing next generation targeted CNS therapies.
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK") Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®, RELVAR®, BREO® and TRELEGY® are trademarks of the GSK group of companies.
Forward Looking Statements
This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words "anticipate", "expect", "goal", "intend", "objective", "opportunity", "plan", "potential", "target" and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus ("COVID-19"); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission ("SEC") and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
INNOVIVA, INC. | ||||||||||||||||
Condensed Consolidated Statements of Income | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenue: | ||||||||||||||||
Royalty revenue, net (1) | $ | 66,165 | $ | 51,216 | $ | 238,846 | $ | 311,645 | ||||||||
Net product sales | 19,675 | 14,587 | 60,617 | 19,694 | ||||||||||||
License Revenue | - | - | 11,000 | - | ||||||||||||
Total revenue | 85,840 | 65,803 | 310,463 | 331,339 | ||||||||||||
Expenses: | ||||||||||||||||
Cost of products sold (inclusive of amortization of inventory fair value adjustments) | 13,130 | 10,113 | 41,040 | 13,793 | ||||||||||||
Cost of license revenue | - | - | 1,600 | - | ||||||||||||
Selling, general and administrative | 26,319 | 17,454 | 98,232 | 63,538 | ||||||||||||
Research and development | 2,356 | 9,985 | 33,922 | 41,432 | ||||||||||||
Amortization of acquired intangible assets | 6,510 | 4,070 | 21,784 | 5,581 | ||||||||||||
Gain on TRC sale | - | - | - | (266,696 | ) | |||||||||||
Loss on debt extinguishment | - | - | - | 20,662 | ||||||||||||
Changes in fair values of equity method investments, net | (9,506 | ) | 117,274 | (77,392 | ) | 161,749 | ||||||||||
Changes in fair values of equity and long-term investments, net | (16,016 | ) | (31,868 | ) | (11,129 | ) | (8,462 | ) | ||||||||
Interest and dividend income | (4,786 | ) | (3,188 | ) | (15,818 | ) | (6,369 | ) | ||||||||
Interest expense | 5,952 | 4,028 | 19,157 | 15,789 | ||||||||||||
Other expense (income), net | 680 | 2,623 | 4,969 | 3,373 | ||||||||||||
Total expenses | 24,639 | 130,491 | 116,365 | 44,390 | ||||||||||||
Income before income taxes | 61,201 | (64,688 | ) | 194,098 | 286,949 | |||||||||||
Income tax expense | (330 | ) | 3,626 | 14,376 | 66,687 | |||||||||||
Net income | 61,531 | (68,314 | ) | 179,722 | 220,262 | |||||||||||
Net income attributable to noncontrolling interest | - | - | - | 6,341 | ||||||||||||
Net income attributable to Innoviva stockholders | $ | 61,531 | $ | (68,314 | ) | $ | 179,722 | $ | 213,921 | |||||||
Basic net income per share attributable to Innoviva stockholders | $ | 0.97 | $ | (0.98 | ) | $ | 2.75 | $ | 3.07 | |||||||
Diluted net income per share attributable to Innoviva stockholders | $ | 0.76 | $ | (0.98 | ) | $ | 2.20 | $ | 2.37 | |||||||
Shares used to compute basic net income per share | 63,710 | 69,656 | 65,435 | 69,644 | ||||||||||||
Shares used to compute diluted net income per share | 84,995 | 69,656 | 86,876 | 95,248 | ||||||||||||
(1) Total net revenue is comprised of the following (in thousands): | |||||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||||
December 31, | December 31, | ||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||
(unaudited) | (unaudited) | ||||||||||||||||
Royalties | $ | 69,620 | $ | 54,671 | $ | 252,669 | $ | 325,468 | |||||||||
Amortization of capitalized fees | (3,455 | ) | (3,455 | ) | (13,823 | ) | (13,823 | ) | |||||||||
Royalty revenue, net | $ | 66,165 | $ | 51,216 | $ | 238,846 | $ | 311,645 | |||||||||
INNOVIVA, INC. | |||||||
Condensed Consolidated Balance Sheets | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
December 31, | December 31, | ||||||
2023 | 2022 | ||||||
Assets | |||||||
Cash and cash equivalents | $ | 193,513 | $ | 291,049 | |||
Royalty and product sale receivables | 84,075 | 64,073 | |||||
Inventory, net | 40,737 | 55,897 | |||||
Prepaid expense and other current assets | 25,894 | 32,492 | |||||
Property and equipment, net | 483 | 170 | |||||
Equity and long-term investments | 560,978 | 403,013 | |||||
Capitalized fees | 83,784 | 97,607 | |||||
Right-of-use assets | 2,536 | 3,265 | |||||
Goodwill | 17,905 | 26,713 | |||||
Intangible assets | 230,335 | 252,919 | |||||
Other assets | 3,267 | 4,299 | |||||
Total assets | $ | 1,243,507 | $ | 1,231,497 | |||
Liabilities and stockholders’ equity | |||||||
Other current liabilities | $ | 33,435 | $ | 32,322 | |||
Accrued interest payable | 3,422 | 4,359 | |||||
Deferred revenues | 1,277 | 2,094 | |||||
Convertible subordinated notes, due 2023, net | - | 96,193 | |||||
Convertible senior notes, due 2025, net | 191,295 | 190,583 | |||||
Convertible senior notes, due 2028, net | 254,939 | 253,597 | |||||
Other long term liabilities | 71,870 | 70,918 | |||||
Deferred tax liabilities | 563 | 5,771 | |||||
Income tax payable - long term | 11,751 | 9,872 | |||||
Innoviva stockholders’ equity | 674,955 | 565,788 | |||||
Total liabilities and stockholders’ equity | $ | 1,243,507 | $ | 1,231,497 | |||
INNOVIVA, INC. | ||||||||
Cash Flows Summary | ||||||||
(in thousands) | ||||||||
(unaudited) | ||||||||
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
Net cash provided by operating activities | $ | 141,064 | $ | 201,726 | ||||
Net cash used in investing activities | (66,761 | ) | (56,634 | ) | ||||
Net cash used in financing activities | (171,839 | ) | (55,568 | ) | ||||
Net change | $ | (97,536 | ) | $ | 89,524 | |||
Cash and cash equivalents at beginning of period | 291,049 | 201,525 | ||||||
Cash and cash equivalents at end of period | $ | 193,513 | $ | 291,049 | ||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229441244/en/
Contacts
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
